HyGIeaCare® Receives First Patent from USPTO

HyGIeaCare’s patent covers a system for treatment and/or diagnosis utilizing a colon irrigation system together with novel analytical features

AUSTIN, TX, UNITED STATES, September 28, 2017 /EINPresswire.com/ — HygieaCare Inc. announced today that the USPTO has notified the Company that on October 3rd its US Patent application will be issued as USP Number 9775865. The patent relates to systems for characterization of the contents of the large intestine and treatment of conditions of the large intestine.

The patent covers a system for treatment and/or diagnosis of a condition in a patient's large intestine utilizing a colon irrigation system and an analysis module configured in a certain manner, together with additional novel analytical features including an acoustic array to listen to the colon for noise mapping and potential identification of conditions, a camera to enable visual diagnosis based on excretions, and therapeutic infusion of donor stool, autologous stool or other therapeutic compounds based on the analysis of excreted stool. Also covered under this patent is a stool bank for large intestine contents' samples from patients performing colon irrigation, associated with derived microbiome characteristics of these samples.

Since inception in 2015 HyGIeaCare has established HyGIeaCare Centers providing bowel preparation without all the associated side effects of the current preparation and with consistently high cleanliness rates. More than 5,000 patients have performed the prep with 97% of them having an adequately clean colon, with ZERO severe adverse events and excellent patient and physician feedback. This technology is now being increasingly implemented in a growing number of leading GI groups in the US. With increasing adoption, HyGIeaCare will establish a Platform upon which additional patented offerings can be stacked, enhancing the value of each Center while creating higher barriers of entry.

“This patent allows HyGIeaCare to potentially be a unique player in the field of microbiome research aimed at providing new diagnostic and therapeutic paths for diseases in the population,” said Gavriel Meron, Chairman and CEO of HyGIeaCare. “This paves the path for HyGIeaCare to consistently gather stool samples for microbiome analysis from regions in the GI tract that currently cannot readily be sampled.”

For more information about HyGIeaCare® please go to: http://www.hygieacare.com

About HyGIeaCare, Inc.
Chairman and CEO Gavriel (Gabi) Meron – the founder and former CEO of Given Imaging, the Company that successfully brought the PillCam to the world – partnered with Texas-based Lifestream Purification Systems to form HyGIeaCare, Inc. to bring the HyGIeaCare FDA-cleared Prep System and procedure exclusively to the GI world.

The goal of HyGIeaCare (www.hygieacare.com) is to provide unique services and solutions to gastroenterologists to deliver better GI outcomes for their patients and their practice through HyGIeaCare Centers to be established in the US and throughout the world.

Michal Gorodish Vice President Marketing
hygieacare inc.
(470) 819-8351
email us here

Source: EIN Presswire

CVR Medical Bolsters Finance, Quality Systems with Knisley

CVR Medical Corp. (OTCQB:CRRVF)

VANCOUVER, BRITISH COLUMBIA, CANADA, September 28, 2017 /EINPresswire.com/ —

CVR Medical Corp. (TSX.V: CVM) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical”) announces the addition of Mr. Tim Knisley as Director of Finance and Controlling. Knisley will spearhead the building of CVR’s financial systems as they transition from research and development-based to commercial-ready with the launch of the “Carotid Stenotic Scan (CSS)” device.

Mr. Tim Knisley has worked in the medical device industry for over twenty years, successfully managing finances and plant controls for several manufacturing companies, including Kendall, Tyco, and the German multinational corporation Beiersdorf AG. With an expert knowledge of medical device company accounting and finance systems, his work will focus on preparing CVR for the fundamental shift to revenue and cost structures associated with commercial sales. In addition, he is a certified Lean 6 Sigma Green Belt and Lead Internal Auditor, and his experience with the engineering change notice process and control documentation will provide tangible value to CVR’s quality management systems.

CVR CEO Peter Bakema states, “We are very pleased to share the addition of Tim Knisley to our staff. His role will be integral to allowing us to transition seamlessly into the next financial phase of the company. His knowledge of quality controls will also help ensure that our supply chain management functions reflect the efficiency and excellence of our partner, Canon.”

“I’m excited to join the CVR team,” says Knisley. “This is a talented, hardworking team with talented individuals that have a shared vision of reducing stroke and the impact it has on its victims. Having seen that impact personally, through my grandfather’s stroke and the debilitated state that it left him in for the remainder of his life, the lasting impression I had was that this is something we need to fix. The opportunity to contribute to what CVR is doing is one that is truly special because the CSS is a device that can and will save lives.”

For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
(signed) "Peter Bakema"
CEO, President & Director

For further information contact:
Peter Bakema, CEO, President and Director
Telephone: (734) 718-5115
Email: info@cvrmed.com
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.


Peter Bakema
CVR Medical Corp.
email us here

Source: EIN Presswire

Author Penned Hope for Bipolar and Empower Others

Mind, Pain, Feeling, Healing

Author Penned Hope for Bipolar and Empower Others

ORLANDO, FL, UNITED STATES, September 28, 2017 /EINPresswire.com/ — The book is a groundbreaking tale of real struggles with bipolar disorder. In her book, Mind, Pain, Feeling, Healing, the author Lois E. Lund gives a raw and in-the-moment account of what she feels and thinks.

This book identifies existing problems that affect people with the said disorder, discusses all the rough edges, inequities with all honesty.

The book gives a thorough account of the writer's journey, her passion, adulation, and emotional health. It also commends the people that gave her the touching support to overcome the hurdles of being bipolar and the lessons she learned along the way.

While others tried to conceal it, Lund provides hope and revelations in her book. Each page will chronicle the anxiety, stress, as well as symptoms to allow her readers to understand what most bipolar experience and what solutions shall be taken to overcome or remedy the illness. Mind, Pain, Feeling, Healing becomes the voice of the unheard for those who still hide in fear.

Readers will have clarity and as the reading progress, they never would undermine the seriousness of bipolar disorder. She perfectly consolidates her thoughts with courage and wants her readers to inherit her bravery for facing bipolar, especially military veterans, who like herself, had to suffer in silence.

Hope, healing and facing life with courage is the book’s main purpose. It will not only tell a story but will impart life's lessons as well.

About the Author:
Lois Lund has a passion for entertaining young children with rhyming poetry and stories that encourage reading and imaginative play. From baby chicks as yellow as butter to a froggie who can leap, Lund leads youngsters through a variety of catchy poems and true tales that reflect on things children love, encourage a good work ethic at home and at school, honor God, and teach about times gone by. In this colorful collection of poetry and stories, children learn that life is always more fun when they focus on faith, love, and happiness. Lois Lund grew up in a small town in Indiana, earned an Associate's degree in Arts from Valencia Community College, and served in the United States Navy. She and her husband have a daughter and live in Orlando, Florida, where she enjoys playing the trumpet in church.

Product details:
Paperback: 48 pages
Publisher: AuthorHouse (September 14, 2015)
Language: English
ISBN-10: 1504947193
ISBN-13: 978-1504947190
Product Dimensions: 5 x 0.1 x 8 inches

Book Availability:
Amazon – http://goo.gl/vfufpb
AuthorHouse – http://goo.gl/SGyDdT

Lois E. Lund
email us here

Source: EIN Presswire

Matrix Achievement Group Adds Neuroscience: The Best Presenter™ to Suite of Services

This new program will focus on the neuroscience of effective communication.

MEMPHIS, TN, UNITED STATES, September 28, 2017 /EINPresswire.com/ — Matrix Achievement Group, LLC, a global leader in sales force effectiveness, announces the addition of Neuroscience: The Best Presenter™ to their comprehensive portfolio of assessments, live training, and mobile solutions. This program will highlight the importance of understanding the neuroscience of effective communication, beyond the current market offerings that focus on outdated presentation skills.

“Neuroscience: The Best Presenter™ is a natural fit with our award-winning suite of services, as we’ve focused on an “end-to-end” solution for the lifecycle and competency needs of leaders, managers, and sales professionals,” said CEO, Todd Zaugg. “We are grateful for earning industry recognition for our insights on customer decision making, performance coaching, negotiations, and many other aspects of the sales cycle,” continued Zaugg.

The program was built in tandem with world-class experts and a focus on the knowledge that effective communication skills are critical for all professionals. Neuroscience: The Best Presenter™ aims to teach the skills required to engage, command and inspire an audience. One and two day sessions are available. For more information, visit MXBestPresenter.com or Matrixachievement.com.

“With this new program, we enter into a topic and market that has become stale with the same old concepts. Our program helps any speaker use neuroscience to transform the messenger and the message, assuring that they win before they begin,” said Zaugg.


About Matrix Achievement Group
Matrix Achievement Group is a boutique, global sales force effectiveness and performance improvement consulting firm. The Matrix mission is to assist companies in developing and sustaining competitive business advantage. Matrix leverages a comprehensive world-class portfolio of solutions to accelerate talent development.

Lori McConville
McConville Consulting
email us here

Source: EIN Presswire

USG Announces Keynote Speakers for its III International Conference on Vaccines Research & Development in Washington DC

PLANO, TEXAS, UNITED STATES OF AMERICA, September 28, 2017 /EINPresswire.com/ — United Scientific Group (USG) recently announced its world-class lineup of speakers, sponsors and exhibitors for III International Conference on Vaccines Research & Development (Vaccines R&D 2017). This year’s event will be held November 13-15 at the Sheraton Reston Hotel, Reston located within the Washington, D.C. metropolitan area with a gathering of over 250 prominent researchers from academia, industry and government agencies from over 20 countries around the world.

“After two successful annual meetings in 2015 and 2016 at Baltimore, MD, United States and Cartagena, Colombia, respectively, we are excited and pleased again to see that many influential leaders have committed to speak at Vaccines R&D-2017. Their experience and leadership in the international vaccine market will allow for critical and insightful discussions at the venue” commented Dr. Suds Yakkanti, Associate Vice President, United Scientific Group.

I. Keynote speakers to kick-off Vaccines R&D-2017: On November 13, the Vaccines R&D-2017 general session will feature keynote address from the stalwarts in the field to stimulate productive thinking and scientific exchange with ground breaking vaccine research and discussion of the challenges and future of immunization.

Speakers include:
Jay A. Berzofsky, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Nancy Sullivan, Biodefense Research Section, NIAID, NIH, Bethesda, MD, USA
Roy Curtiss, III, Department of Infectious Diseases & Immunology, College of Veterinary Medicine, University of Florida, Gainesville, FL, USA
Peter L. Nara, Biological Mimetics, Inc., Frederick, MD, USA
Manuel Elkin Patarroyo M, Foundation Institute of Immunology of Colombia – FIDIC, Bogotá DC – Colombia, SA
Stephen L. Hoffman, Sanaria Inc., Rockville, MD, USA
Michael G. Hanna, Vaccinogen Inc., Baltimore, MD, USA
Odile Leroy, European Vaccine Initiative, Germany
Pierre A. Morgon, MRGN Advisors, Switzerland
David B. Weiner, The Wistar Institute, Philadelphia, PA, USA

II. The long road to an HIV vaccine _ Symposium: In view of the overwhelming importance of the HIV pandemic and the huge R&D efforts currently underway to develop an HIV vaccine, we believe it would be justified to devote a full day (November 14) symposium on HIV vaccine development with the Title: “The long road to an HIV vaccine”

Speakers include:
Susan Zolla-Pasner, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Hanneke Schuitemaker, Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines and Prevention, The Netherlands
Louis Picker, Oregon Health & Science University, OR, USA
Neil S. Greenspan, Case Western Reserve University, Cleveland, OH, USA
Marc H V Van Regenmortel, University of Strasbourg, France

These are keynote speakers among more than 20 high profile speakers from both academia and industry who will address the symposium.

III. Special session on vaccine regulation: A special session on Vaccine Regulation with a theme “Challenges for registration of vaccines at global level” is scheduled to discuss and share the regulatory aspects in the vaccine evaluation and approval process.

Speakers include:
Nora Dellepiane, Serum Institute of India Pvt. Ltd, India
Kelsy Hofman, CBER/FDA
Bartholomew Dicky Akanmori, WHO/Afro
In this scientific gathering, one can attend keynote and featured sessions led by over 150 experts focusing on key areas like: cancer and immunotherapy, emerging and re-emerging diseases, influenza and other respiratory diseases, bioprocessing and manufacturing, clinical trials, HIV, passive vaccines, therapeutic vaccination, veterinary immunization, vaccine production technologies, bioprocessing & manufacturing, and partnerships.

The lead sponsors and exhibitor for the Vaccines R&D-2017 are Mucosis, Sanofi Pasteur and GenScript respectively.

To register or learn more about the conference, PS: http://www.unitedscientificgroup.com/conferences/vaccines/

About Organizer:
United Scientific Group (USG), an expert-driven initiative led by the editors’ association and the advisory board which includes academicians, researchers, and industry leaders across various fields of research. USG provides a broad range of services in the fields of science and technology including publishing, conducting world class scientific events, and holding highly interactive and productive world forums. For more information, please visit: http://unitedscientificgroup.com/

Mr. Venky and Dr. Dasari
United Scientific Group, LLC
email us here

Source: EIN Presswire

Genohm: Revolutionizing Lab Operation Digitization with SLIMS and Isomorphic Software's Smart GWT

Genohm is digitizing modern lab operations with their SLIMS web application – built with Isomorphic Software’s Smart GWT technology

SAN FRANCISCO, CALIFORNIA, UNITED STATES, September 28, 2017 /EINPresswire.com/ — Modern lab technologies such as next-generation sequencing (NGS) can generate millions of results from each test. Manual paper-based systems are therefore obsolete. There are solutions available to manage lab processes and results, but they have limitations and are cost prohibitive. Genohm CEO – Frederick Decouttere – saw this as an opportunity and built the revolutionary ‘SLIMS’ web application. SLIMS is an affordable, highly flexible, combined Laboratory Information Management System (LIMS) and Electronic Lab Notebook (ELN) platform.

SLIMS’ power and flexibility have proven to meet the needs of labs around the globe performing research, NGS, diagnostics, Biobanking and digital pathology. With SLIMS, Genohm has rocketed from startup to a top 5 global player, and boasts an impressive international client list which includes the FDA.

When Decouttere set out, he knew that to be successful, SLIMS would have to offer Excel-like capabilities via any standard web browser (plugin free). It would have to be flexible, have a feature rich and highly productive UI, and be able to handle volume data at high speed. All this was not as challenging as Decouttere imagined.

After experimenting with several technologies, Genohm selected Smart GWT from Isomorphic Software to build SLIMS. They made the right choice. According to Decouttere “With Isomorphic’s Smart GWT, our developers are hyper-productive: It takes care of everything on both the client and server side, with its very complete GUI component toolkit, data binding systems and intelligent data management”.

With the latest SLIMS release – 6.0 – cloud deployment is available, making rollout, security, maintenance and scalability considerations a thing of the past.

To learn more about SLIMS, visit www.genohm.com.
To learn more about Smart GWT, visit www.SmartClient.com.

About Genohm
Genohm’s history starts in 2002 as a spin-off of the University of Ghent, Belgium. Launched as a 2 person bio-informatics shop, the company has kept building up an extensive bio-informatics expertise within the life sciences R&D world. In 2010, Genohm released SLims, a digital platform providing laboratories with an integrated LIMS + ELN environment to enter the lab informatics market.
In 2011, Genohm opened its new HQ at the EPFL Innovation Park in Lausanne, Switzerland and in 2016 a US branch in Durham, NC. Today Genohm serves a growing set of customers in Europe, the Middle East and the US.
Genohm is ISO 9001 certified.

SLIMS is a digital platform used for managing all information in a laboratory. It is an all-in-one complete package which allows customers to track samples, interact with lab equipment and offers full data lifecycle management. SLIMS provides laboratories with one integrated Laboratory Information Management System (LIMS) + Electronic Lab Notebook (ELN) environment that tracks data and samples from the original sample shipment down to the result from lab machines and in-silico analysis pipelines.
The platform provides an environment to support the increasing complexity of handling, sharing, analyzing and understanding data generated by any laboratory active in research, next-generation sequencing, diagnostics or biobanking. Currently used by over 60 labs worldwide, from small research facilities up to large governmental institutions, SLIMS helps scientists manage millions of samples and results.

About Isomorphic Software
Isomorphic Software is based in San Francisco and has over a decade of industry leadership, providing technology platforms for building enterprise web applications. Companies around the world use the SmartClient Platform, including Cisco, Boeing, Toyota, Philips and Genentech.

About Smart GWT
Isomorphic Software's Smart GWT allows developers to build better applications faster. It is part of SmartClient Platform – the most mature, technically advanced technology for building rich, high-productivity enterprise applications. SmartClient provides applications a depth and breadth of capabilities that is unrivaled: Enterprise Grade UI components, Intelligent Data Management, and Deep Server Integration.


Isomorphic Software
(415) 222-9902
email us here

Source: EIN Presswire

ASCP Selects Halfpenny Technologies to Drive Patient-Centric National Pathology Quality Registry

ASCP announces the selection of Halfpenny Technologies as its clinical data exchange partner to power the National Pathology Quality Registry (NPQR).

BLUE BELL, PA, UNITED STATES, September 28, 2017 /EINPresswire.com/ — ASCP Selects Halfpenny Technologies to Drive Patient-Centric National Pathology Quality Registry


The American Society for Clinical Pathology (ASCP) announces the selection of Halfpenny Technologies as its clinical data exchange partner to power the National Pathology Quality Registry (NPQR).

NPQR is a quality improvement and benchmarking program ASCP established in 2016. The registry is launching in fall 2017.

The NPQR aims to improve patient outcomes by helping laboratories assess and optimize their quality and performance in key ways:
• Monitoring appropriate utilization of laboratory testing.
• Improving pre-analytical processes.
• Optimizing turnaround time and critical value reporting.
• Establishing best practices through national and peer group comparisons.
• Assessing analytical and diagnostic accuracy.

Additionally, ASCP members and others who participate will be able to use NPQR to satisfy quality reporting requirements from the Centers for Medicare and Medicaid Services’ (CMS) Quality Payment Program (QPP), under the Merit-based Incentive Payment System (MIPS).

Jeff Jacobs, the Chief Officer of Science, Technology, and Policy at ASCP, made the following statement: “ASCP is looking forward to working with the Halfpenny team to build the National Pathology Quality Registry. We performed an extensive national search through our partner IMPAQ Strategy to find the very best clinical data integration partner. We chose Halfpenny Technologies for clinical data exchange because of their industry-leading expertise in managing the exchange of patient data. We believe the registry will be very well received in the medical community and have long lasting positive impact to our clients and their patients.”

“Our extensive experience working with disparate Anatomic Pathology and Laboratory Information Systems with large, complex integration projects will facilitate collecting and normalizing the data from the Participating Registry Organizations.”, said Tim Kowalski, President and CEO of Halfpenny Technologies. “We are excited to be partnering with the premier Registry in the industry, helping them improve patient care.”

NPQR will emphasize elements amenable to integration within existing laboratory information systems (LISs) to minimize the need for manual data entry, and thus break down barriers for laboratories and practices to participate.

About ASCP
Founded in 1922 in Chicago, ASCP is a medical professional society with more than 100,000 member board-certified anatomic and clinical pathologists, pathology residents and fellows, laboratory professionals, and students. ASCP provides excellence in education, certification, and advocacy on behalf of patients, pathologists, and laboratory professionals. To learn more, visit http://www.ascp.org. Follow us on Twitter at http://www.twitter.com/ascp_chicago and connect with us on Facebook at http://www.facebook.com/ASCP.Chicago.

About Halfpenny Technologies
Halfpenny Technologies is a leading provider of healthcare interoperability solutions enabling meaningful clinical data exchange. Our cloud-based, fully-managed solutions provide hospitals, labs, health plans, pharmacies, and HIEs with a secure, vendor-neutral infrastructure that supports care coordination, care management, regulatory requirements and data analysis within and between healthcare organizations. To learn more, visit www.halfpenny.com. Follow us on Twitter at https://twitter.com/halfpennytech and follow us on LinkedIn at https://www.linkedin.com/company/halfpenny-technologies.

Ali Brown, MD, FASCP, Medical Director

Halfpenny Technologies Inc.
Jack Redding, SVP of Sales and Marketing
610-277-9100 X151

Jack Redding
Halfpenny Technologies
610-277-9100 ext. 151
email us here

Source: EIN Presswire

Marketing Approval for Infliximab Biosimilar 100mg "Nichi-Iko" in Japan

Sagent Pharmaceuticals Announces U.S. Infliximab Phase III Study Underway

SCHAUMBURG, ILLINOIS, UNITED STATES, September 28, 2017 /EINPresswire.com/ — Sagent Pharmaceuticals, Inc., a wholly-owned subsidiary of Nichi-Iko Pharmaceuticals Co. Ltd., is pleased to announce that Nichi-Iko’s application for marketing approval of their infliximab biosimilar for intravenous (I.V.) infusion 100mg “Nichi-Iko” was approved by the Ministry of Labour, Health, and Welfare in Japan earlier today.

Nichi-Iko initiated the overseas development of their infliximab candidate with a phase III clinical trial in the U.S. Based on consultations with the U.S. Food and Drug Administration (FDA), the phase III RADIANCE (NCT02990806) study is underway to demonstrate that infliximab is interchangeable with US-Licensed Remicade®1 (infliximab) in patients with rheumatoid arthritis not adequately responding to methotrexate.2

RADIANCE represents the first clinical trial that will demonstrate interchangeability in the U.S. for an infliximab candidate. Interchangeable biosimilars are defined by the FDA as products that are expected to produce the same clinical result as an FDA-approved reference product in any patient.3 A product that is awarded the interchangeability designation by the FDA may be exchanged for the reference product without the intervention of the prescribing health care provider, subject to individual state law.

Marketing and distribution of infliximab in the U.S. would be conducted by Sagent Pharmaceuticals. Going forward, Sagent will launch a website for additional information regarding interchangeability and biosimilars at www.SagentBiosimilars.com.

1. Remicade® is a registered trademark of Janssen Biotech
2. ClinicalTrials.gov. ‘A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)’. [Online] Available at: https://clinicaltrials.gov/ct2/show/NCT02990806?term=ni-071&rank=2 [Accessed: September 2017].
3. U.S. Food & Drug Administration. ‘Information for Healthcare Professionals (Biosimilars)’. [Online] Available at: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm241719.htm [Accessed: September 2017]

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc., a Nichi-Iko group company, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. For more information, visit www.SagentPharma.com

About Nichi-Iko Pharmaceutical Co.

Nichi-Iko Pharmaceutical Co., Ltd is a leading generic pharmaceutical company in Japan, engaging in the manufacture, distribution, export, import and sale of generic drugs and other medical products. Nichi-Iko was founded in 1965 and is headquartered in Toyama, Japan. For more information, visit www.nichiiko.co.jp/english

Diane Lilli
JTP Press
email us here

Source: EIN Presswire

Organic Food – Global Industry Size, Share, Trends, Analysis and Forecast 2017 – 2022

Wiseguyreports.Com Adds “Organic Food Market: Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database

PUNE, INDIA, September 28, 2017 /EINPresswire.com/ — This report studies Organic Food in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering
Conscious Food
Organic India
Morarka Organic Foods
Gayatri Organic Foods
Sresta Natural Bioproducts
Navdanya Foods
Suminter India Organics
Fabindia Overseas
Pristine Organics

Request a sample report @ https://www.wiseguyreports.com/sample-request/893232-global-organic-food-market-research-report-2017

Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of Organic Food in these regions, from 2011 to 2021 (forecast), like
North America
Southeast Asia
Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into
Organic Milk Food
Organic Meat Food
Organic Vegetable Food
Organic Fruit Food
Split by application, this report focuses on consumption, market share and growth rate of Organic Food in each application, can be divided into
Food Industry
Pharmaceutical Intermediates

Complete report details @ https://www.wiseguyreports.com/reports/893232-global-organic-food-market-research-report-2017

Key points in table of content

1 Organic Food Market Overview
1.1 Product Overview and Scope of Organic Food
1.2 Organic Food Segment by Type
1.2.1 Global Production Market Share of Organic Food by Type in 2015
1.2.2 Organic Milk Food
1.2.3 Organic Meat Food
1.2.4 Organic Vegetable Food
1.2.5 Organic Fruit Food
1.3 Organic Food Segment by Application
1.3.1 Organic Food Consumption Market Share by Application in 2015
1.3.2 Food Industry
1.3.3 Pharmaceutical Intermediates
1.4 Organic Food Market by Region
1.4.1 North America Status and Prospect (2012-2022)
1.4.2 Europe Status and Prospect (2012-2022)
1.4.3 China Status and Prospect (2012-2022)
1.4.4 Japan Status and Prospect (2012-2022)
1.4.5 Southeast Asia Status and Prospect (2012-2022)
1.4.6 India Status and Prospect (2012-2022)
1.5 Global Market Size (Value) of Organic Food (2012-2022)

2 Global Organic Food Market Competition by Manufacturers
2.1 Global Organic Food Production and Share by Manufacturers (2015 and 2016)
2.2 Global Organic Food Revenue and Share by Manufacturers (2015 and 2016)
2.3 Global Organic Food Average Price by Manufacturers (2015 and 2016)
2.4 Manufacturers Organic Food Manufacturing Base Distribution, Sales Area and Product Type
2.5 Organic Food Market Competitive Situation and Trends
2.5.1 Organic Food Market Concentration Rate
2.5.2 Organic Food Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Organic Food Production, Revenue (Value) by Region (2012-2017)
3.1 Global Organic Food Production and Market Share by Region (2012-2017)
3.2 Global Organic Food Revenue (Value) and Market Share by Region (2012-2017)
3.3 Global Organic Food Production, Revenue, Price and Gross Margin (2012-2017)
3.4 North America Organic Food Production, Revenue, Price and Gross Margin (2012-2017)
3.5 Europe Organic Food Production, Revenue, Price and Gross Margin (2012-2017)
3.6 China Organic Food Production, Revenue, Price and Gross Margin (2012-2017)
3.7 Japan Organic Food Production, Revenue, Price and Gross Margin (2012-2017)
3.8 Southeast Asia Organic Food Production, Revenue, Price and Gross Margin (2012-2017)
3.9 India Organic Food Production, Revenue, Price and Gross Margin (2012-2017)

4 Global Organic Food Supply (Production), Consumption, Export, Import by Regions (2012-2017)
4.1 Global Organic Food Consumption by Regions (2012-2017)
4.2 North America Organic Food Production, Consumption, Export, Import (2012-2017)
4.3 Europe Organic Food Production, Consumption, Export, Import (2012-2017)
4.4 China Organic Food Production, Consumption, Export, Import (2012-2017)
4.5 Japan Organic Food Production, Consumption, Export, Import (2012-2017)
4.6 Southeast Asia Organic Food Production, Consumption, Export, Import (2012-2017)
4.7 India Organic Food Production, Consumption, Export, Import (2012-2017)

5 Global Organic Food Production, Revenue (Value), Price Trend by Type
5.1 Global Organic Food Production and Market Share by Type (2012-2017)
5.2 Global Organic Food Revenue and Market Share by Type (2012-2017)
5.3 Global Organic Food Price by Type (2012-2017)
5.4 Global Organic Food Production Growth by Type (2012-2017)

6 Global Organic Food Market Analysis by Application
6.1 Global Organic Food Consumption and Market Share by Application (2012-2017)
6.2 Global Organic Food Consumption Growth Rate by Application (2012-2017)
6.3 Market Drivers and Opportunities
6.3.1 Potential Applications
6.3.2 Emerging Markets/Countries

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=893232

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire

Blood Bank Information Management System Market 2017–Global SWOT Analysis,Emerging Market Strategies,Industry Overview

PUNE, INDIA, September 28, 2017 /EINPresswire.com/ —

This report studies the global Blood Bank Information Management System market, analyzes and researches the Blood Bank Information Management System development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like
Roper Industries
Cerner Corporation
Integrated Medical Systems
SCC Soft Computer
Zhongde Gaoye
Blood Bank Computer Systems
Jinfeng Yitong
IT Synergistics
Psyche Systems

Get a Sample Report @ https://www.wiseguyreports.com/sample-request/2352464-global-blood-bank-information-management-system-market-size-status-and-forecast

For more information or any query mail at sales@wiseguyreports.com

Market segment by Regions/Countries, this report covers
United States
Southeast Asia

Market segment by Type, Blood Bank Information Management System can be split into
Blood Donor Management Module
Blood Bank Transfusion Service Module

Market segment by Application, Blood Bank Information Management System can be split into
Blood Station

Ask Query @ https://www.wiseguyreports.com/enquiry/2352464-global-blood-bank-information-management-system-market-size-status-and-forecast

Table Of Contents – Major Key Points

Global Blood Bank Information Management System Market Size, Status and Forecast 2022
1 Industry Overview of Blood Bank Information Management System
1.1 Blood Bank Information Management System Market Overview
1.1.1 Blood Bank Information Management System Product Scope
1.1.2 Market Status and Outlook
1.2 Global Blood Bank Information Management System Market Size and Analysis by Regions
1.2.1 United States
1.2.2 EU
1.2.3 Japan
1.2.4 China
1.2.5 India
1.2.6 Southeast Asia
1.3 Blood Bank Information Management System Market by Type
1.3.1 Blood Donor Management Module
1.3.2 Blood Bank Transfusion Service Module
1.3.3 Other
1.4 Blood Bank Information Management System Market by End Users/Application
1.4.1 Blood Station
1.4.2 Hospital

2 Global Blood Bank Information Management System Competition Analysis by Players
2.1 Blood Bank Information Management System Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
2.2.1 Market Concentration Rate
2.2.2 Product/Service Differences
2.2.3 New Entrants
2.2.4 The Technology Trends in Future

3 Company (Top Players) Profiles
3.1 Roper Industries
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.1.5 Recent Developments
3.2 Haemonetics
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.2.5 Recent Developments
3.3 Cerner Corporation
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.3.5 Recent Developments
3.4 McKesson
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.4.5 Recent Developments
3.5 Mak-System
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.5.5 Recent Developments
3.6 Integrated Medical Systems
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.6.5 Recent Developments
3.7 Mediware
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.7.5 Recent Developments
3.8 Compugroup
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.8.5 Recent Developments
3.9 SCC Soft Computer
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Blood Bank Information Management System Revenue (Value) (2012-2017)
3.9.5 Recent Developments


For more information or any query mail at sales@wiseguyreports.com

Buy 1-User PDF@ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2352464

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire